Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Exp Dermatol. 2013 Mar 12;22(5):303–306. doi: 10.1111/exd.12117

Table 1.

Conceivable applications based on non-coding RNAs.

  • Diagnosis

    • Presence of specific non-coding RNAs as biomarker for tumor (e.g. metastasis)

    • Classification of tumor subgroups (e.g. metastasis risk)

    • Treatment selection

  • Therapy

    • Drugs and RNA therapeutics targeting specifically splice variants

    • Targeting non-coding RNA

    • Targeting epigenetic machinery

    • Influencing RNA/protein levels

    • Immunotherapies based on epitopes derived from non-coding RNAs